Scarica l'app Stockscreener
2.14
13.23%
0.25
Pre-mercato:
2.14
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GANX Giù?
Forum
Previsione
Precedente Chiudi:
$1.89
Aprire:
$1.91
Volume 24 ore:
782.23K
Relative Volume:
1.02
Capitalizzazione di mercato:
$90.93M
Reddito:
$55,200
Utile/perdita netta:
$-20.16M
Rapporto P/E:
-3.4876
EPS:
-0.6136
Flusso di cassa netto:
$-18.47M
1 W Prestazione:
+18.89%
1M Prestazione:
-11.93%
6M Prestazione:
+14.44%
1 anno Prestazione:
+18.89%
Intervallo 1D:
$1.88
$2.15
Intervallo di 1 settimana:
$1.77
$2.15
Portata 52W:
$1.41
$4.34
Gain Therapeutics Inc Stock (GANX) Company Profile
Nome
Gain Therapeutics Inc
Settore
Industria
Telefono
(301) 500-1556
Indirizzo
4800 HAMPDEN LANE, BETHESDA
Compare GANX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
2.14 | 80.30M | 55,200 | -20.16M | -18.47M | -0.6136 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-08-14 | Ripresa | Oppenheimer | Outperform |
| 2021-04-12 | Iniziato | BTIG Research | Buy |
| 2021-04-12 | Iniziato | Oppenheimer | Outperform |
Gain Therapeutics Inc Borsa (GANX) Ultime notizie
Breakout Watch: Does Gain Therapeutics Inc have a sustainable dividendMarket Risk Analysis & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
GANX Should I Buy - Intellectia AI
Technical Analysis: Will Gain Therapeutics Inc benefit from green energy policiesQuarterly Trade Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
GANX Technical Analysis | Trend, Signals & Chart Patterns | GAIN THERAPEUTICS INC (NASDAQ:GANX) - ChartMill
Weekly Recap: Is Gain Therapeutics Inc a strong candidate for buy and holdMarket Sentiment Report & Real-Time Market Trend Scan - baoquankhu1.vn
Death Cross: Is Gain Therapeutics Inc attractive for institutional investorsPortfolio Value Report & Real-Time Stock Entry Alerts - baoquankhu1.vn
Stop Loss: What hedge funds are buying Gain Therapeutics IncInsider Selling & Long-Term Growth Stock Strategies - baoquankhu1.vn
Quarterly Trades: What hedge funds are buying Gain Therapeutics Inc2026 Spike Watch & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Gain Therapeutics Inc. (GANX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
GANX SEC FilingsGain Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX) - The Globe and Mail
HC Wainwright Has Positive Estimate for GANX Q1 Earnings - MarketBeat
Technical Analysis: What are Gain Therapeutics Incs growth levers2026 Momentum Check & Free High Return Stock Watch Alerts - baoquankhu1.vn
Published on: 2026-03-31 06:53:16 - baoquankhu1.vn
H.C. Wainwright reiterates Gain Therapeutics stock rating at buy By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Gain Therapeutics stock rating at buy - Investing.com
Aug Highlights: Is Gain Therapeutics Inc part of any major index2026 Market WrapUp & Daily Growth Stock Tips - baoquankhu1.vn
Analysts Are Bullish on These Healthcare Stocks: Gain Therapeutics (GANX), CG Oncology, Inc. (CGON) - The Globe and Mail
CEO Moves: Is Gain Therapeutics Inc being accumulated by smart money2026 Support & Resistance & Safe Capital Investment Plans - baoquankhu1.vn
Recap Report: What is Gain Therapeutics Incs 5 year growth outlookProduct Launch & Safe Entry Zone Identification - baoquankhu1.vn
Gain Therapeutics (NASDAQ: GANX) grants 50,000 stock options to officer - Stock Titan
Gain Therapeutics (NASDAQ:GANX) Issues Earnings Results - marketbeat.com
Gain Therapeutics 10-K: $(0.61) EPS; $20.8M cash; net loss $(20.16)M - TradingView
Gain Therapeutics reports $20.2M net loss, $20.8M cash at year-end 2025 - TradingView
[10-K] Gain Therapeutics, Inc. Files Annual Report - Stock Titan
Gain Therapeutics (NASDAQ: GANX) 2025 loss narrows as cash doubles - Stock Titan
Gain Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update - Bitget
Gain says its Parkinson’s drug is on track for Phase 2 by 3Q26 - Stock Titan
Gain Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
GANX: Disease-modifying Parkinson's therapy advances to phase II with strong biomarker support - TradingView
Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference - MarketBeat
Parkinson’s therapy shows promise for motor function: Trial data - Parkinson's News Today
Gain Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Aug Volume: Is RDFN stock a buy or sell2026 Market Overview & Verified Momentum Stock Alerts - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX) - The Globe and Mail
Market Moves: What hedge funds are buying Gain Therapeutics IncWeekly Gains Report & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Published on: 2026-03-21 10:38:36 - baoquankhu1.vn
Gain Therapeutics to Present at the 38th Annual ROTH Conference - The Manila Times
Can Gain Therapeutics Inc outperform in the next rallyTrade Entry Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Gain Therapeutics, Inc. CEO Gene Mack to Speak at 38th Annual ROTH Conference - Quiver Quantitative
Gain CEO Gene Mack to speak at ROTH conference on March 23 - Stock Titan
Gain Therapeutics (GANX) Expected to Announce Earnings on Thursday - Defense World
Gain Therapeutics reports biomarker data from Parkinson’s trial By Investing.com - Investing.com South Africa
Gain announces presentations on Phase 1b clinical study of GT-02287 - TipRanks
Gain Therapeutics, Inc. (GANX): Emerging Biomarker Data Strengthens Parkinson’s Drug Pipeline - parameter.io
Gain Therapeutics Presents Positive Phase 1b Results for GT-02287 in Parkinson’s Disease and Advances New GCase Modulators for Clinical Development 123 - Minichart
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data - TipRanks
Gain Presents Phase 1b GT-02287 Data Showing biomarker changes, MDS-UPDRS stability; GT-04686 ready for IND - tradingview.com
Gain Therapeutics Inc Azioni (GANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):